

KILITCH DRUGS (INDIA) LIMITED**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
30TH JUNE 2015**

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

CIN. L24239MH1992PLC066718

Rs. In Lacs

PART. I	Particulars	STANDALONE			
		Quarter Ended		Year ended	
Sr. No.		30/06/2015	31/03/2015	30/06/2014	31/03/2015
		Unaudited	Audited	Unaudited	Audited
1	Income from operations				
	(a) Net Sales/income from operations(net of Excise)	395.74	322.40	556.04	1843.73
	(b) Other operating income	3.67	8.92	14.66	59.00
	Total income from Operations (Net)	399.41	331.32	570.70	1902.73
2	Expenses				
	(a) Cost of materials consumed	298.35	124.06	152.92	648.59
	(b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(13.24)	(4.69)	115.33	53.02
	(c) Employee Benefit Expenses	85.26	74.32	78.94	312.80
	(d) Depreciation and Amortisation Expenses	39.14	19.18	52.81	185.39
	(e) Export Product Registration Charges	14.65	3.16	47.92	110.13
	(f) Other Expenses	285.44	304.57	161.63	946.27
	Total Expenses	709.60	520.60	609.55	2256.20
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(310.18)	(189.28)	(38.85)	(353.47)
4	Other Income	57.62	71.24	66.19	269.02
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	(252.56)	(118.04)	27.34	(84.45)
6	Finance Costs	0.00	0.00	0.00	0.00
7	Profit / (Loss) from ordinary activities before exceptional items (5-6)	(252.56)	(118.04)	27.34	(84.45)
8	Exceptional Items	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7+8)	(252.56)	(118.04)	27.34	(84.45)
10	Tax Expenses				
	Current Tax	0.00	0.00	0.00	0.00
	Deferred Tax	(3.52)	8.69	(22.50)	(65.90)
	Tax Adjustments of Earlier years	0.00	0.00	0.00	0.00
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	(249.05)	(126.73)	49.84	(18.55)
12	Extra Ordinary Items (net of tax expenses)	0.00	0.00	0.00	0.00
13	Net Profit / (Loss) for the period (11+12)	(249.05)	(126.73)	49.84	(18.55)
14	Paid-Up equity share capital (Face Value Rs 10 per share)	1323.18	1323.18	1323.18	1323.18
15	Reserve excluding Revaluation Reserve [As per the latest Audited Balance Sheet]				10674.36
16.i	Earnings per share (before extra ordinary items) (F.V. of Rs.10/-each) (not annualised):				
	(a) Basic	(1.88)	(0.96)	0.38	(0.14)
	(b) Diluted	(1.88)	(0.96)	0.38	(0.14)
16.ii	Earnings per share (after extra ordinary items) (F.V. of Rs.10/-each) (not annualised):				
	(a) Basic	(1.88)	(0.96)	0.38	(0.14)
	(b) Diluted	(1.88)	(0.96)	0.38	(0.14)



A.M.GHELANI & COMPANY
CHARTERED ACCOUNTANTS

AJIT M. GHELANI
B.Com.(Hons), F.C.A, GRAD.C.W.A.

CHINTAN A. GHELANI
B.Com.(Hons), F.C.A, C.S.


INDEPENDENT AUDITORS' REVIEW REPORT

To,
The Board of Directors
KILITCH DRUGS (INDIA) LIMITED

**LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF
KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 30th JUNE, 2015**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** for the quarter ended 30th June, 2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the Accounting Standards issued under the Companies (Accounting Standards) Rules, 2006 which continue to apply as per Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rule, 2014 and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement with the Stock Exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement..

For A. M. Ghelani & Company
Chartered Accountants
(Firm Registration No. 103173W)


Chintan A. Ghelani
Partner
Membership No. 104391



Place: Mumbai
Date: 14-08-2015

Enclosed: Unaudited Standalone financial results for the quarter ended 30th June, 2015 of **Kilitch Drugs (India) Limited**.